What does BTIG maintaining a Buy mean for the ALDX analyst rating?

BTIG maintaining a Buy keeps a constructive ALDX analyst rating in place, signaling belief in upside if regulatory clarity arrives within the next 90 days. It is supportive but not a guarantee of near-term gains for Aldeyra Therapeutics, Inc.

Did BTIG set a new ALDX price target with its March 17 note?

No, BTIG’s March 17 note emphasized regulatory timing and did not publish a new ALDX price target. The firm focused on the CRL being contestable and a likely path to clarity within 90 days.

How should investors use the ALDX analyst rating in their decisions?

Use the ALDX analyst rating as one input among fundamentals, regulatory updates, and risk tolerance. Combine analyst views, Aldeyra’s filings, and Meyka AI tools before acting, since analyst opinions can diverge after regulatory events.

Analyst Ratings

BTIG Maintains Buy on Aldeyra Therapeutics, Inc. (ALDX) March 2026

ByHuzaifa Zahoor March 19, 2026March 19, 2026

BTIG maintained a Buy on Aldeyra Therapeutics, Inc. (ALDX) on March 17, 2026, signaling continued analyst support after the company received an FDA CRL. The ALDX analyst rating from BTIG emphasizes a short window for clarity, noting a likely path to resolution within 90 days. BTIG called the CRL “hard to defend,” yet kept conviction that upcoming regulatory or data developments could restore upside. This maintained Buy contrasts with at least one other firm moving more bearish after the FDA action.